Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|October 7, 2014
New Dimensions in Microwave Synthesis
Anton Paar?s Masterwave Benchtop Reactor employs a revolutionary technique for efficient microwave heating of a sealed 1L reaction vessel.
Advertisement
New Dimensions in Microwave Synthesis
Anton Paar’s Masterwave Benchtop Reactor employs a revolutionary technique for efficient microwave heating of a sealed 1L reaction vessel.
With 1700 W microwave output power up to 750 mL operation volume can be processed at 250 °C and 30 bar covering the vast majority of yet developed microwave reactions. An integrated cooling circuit ensures rapid cooling for short overall reaction cycles.
A built-in agitator provides effective stirring for individual contents to improve productivity.
Accurate temperature measurement is accomplished by an internal temperature sensor. This is essential for direct methods transfer from the R&D scale to kilolab production.
The compact batch-type setup fits in any standard fume hood and allows processing of heterogeneous mixtures, highly viscous content, and slurries. Therefore, the reactor can be applied both in the pharmaceutical industry to produce APIs and in material science for the preparation of nanomaterials, functional polymers and lubricants.
Anton Paar GmbH
Website:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement